



Quality Assurance in Laboratory Testing for IEM

EQA Schemes Catalogue and Participant Guide 2027

ERNDIM Administration Office

c/o EMQN CIC
Third Floor, ICE Building,
3 Exchange Quay, Salford
M5 3ED, United Kingdom
Tel: +44 161 757 4952
Fax: +44 161 850 1145
E-mail: admin@erndim.org
Web: www.erndim.org

Contents

1. Introduction	3
2. EQA Schemes	4
2.1. Quantitative Schemes	4
ACS Acylcarnitines in Serum.....	4
LIS Lipids in Serum	4
PPU Purines and Pyrimidines (urine).....	5
QTAS Quantitative Amino Acids (serum).....	5
QTOU Quantitative Organic Acids (urine).....	5
SADB Special Assays in dried blood spots.....	6
SAS Special Assays in Serum.....	6
SAU Special Assays in Urine.....	6
SAC Special Assays Combined (serum & urine).....	6
2.1.1. Quantitative EQA Schemes' summary.....	7
2.2. Hybrid Schemes	8
CWBC Cystine in White Blood Cells.....	8
LEFB Lysosomal Enzymes (fibroblasts).....	8
NCSF Neurotransmitters in CSF.....	8
PTU Pterins in Urine.....	9
2.2.1. Hybrid EQA Schemes' summary.....	10
2.3. Qualitative Schemes	11
ACDB Acylcarnitines in dried blood spots.....	11
AAI Amino Acids Interpretation.....	11
CDG Congenital Disorders of Glycosylation (plasma/serum).....	12
DPT Diagnostic Proficiency Testing (urine).....	12
QLOU Qualitative Organic Acids (urine).....	12
UMPS Urine Mucopolysaccharides.....	13
2.3.1. Qualitative EQA Schemes' summary.....	14
3. 2027 Calendar (provisional)	15
4. 2027 Price List	16
5. Participation Guide.....	17
6. Terms and Conditions of EQA Scheme Participation	23

Version Date	Amendments
01 September 2026	2027 EQA Catalogue published

1. Introduction

ERNDIM is an independent, not-for-profit foundation that has been delivering External Quality Assurance (EQA) schemes in the field of inborn errors of metabolism since 1994. Originally established as a European initiative, ERNDIM has grown into a global organisation, now supporting over 420 participants across more than 60 countries. As of 2026, approximately 40% of our participants are based outside Europe.

All ERNDIM schemes are designed and overseen by our Scientific Advisory Board, which comprises 23 leading scientists from 10 countries. Full details of the 2027 EQA schemes are available in **Section 2 (pages 4–14)**, and guidance on how to register is provided in **Section 5 (pages 17–22)**. Some activities are subcontracted to scheme organisers however ERNDIM remains responsible for all work. For further details see the Summary tables for each type of scheme (pages 7, 10 and 14) and Section 5.17 (page 20).

The **Participants' Guide** (pages 17–22) contains essential information on scheme participation, including registration procedures, use of EQA data in publications, and payment instructions. For any queries related to the guide, please contact us at admin@erndim.org.

Please also review the **Terms and Conditions of Participation** (pages 23–24). These must be accepted by your centre's primary contact upon first login to the ERNDIM Registration Website, once registration for the 2027 schemes opens. If you have any questions about the terms and conditions, please contact admin@erndim.org.

2. EQA Schemes

2.1. Quantitative EQA Schemes

The main purpose of the Quantitative schemes is to evaluate the ability of the participating laboratories to quantitatively analyse the concentrations of the analytes included in each scheme. The schemes assess accuracy with respect to consensus target values, as well as recovery of spiked analytes, analytical precision and linearity.

Details of the analytes included in each Quantitative scheme are below and full details of the scheme design (type and number of samples, subcontracted activities etc.) are given in section 2.1.1 on page 7.

Cluster Laboratories

Each participating laboratory must produce its own results and cannot send samples to a subcontracted or cluster laboratory. **The use of cluster laboratories is therefore not allowed in any of the Quantitative schemes.**

Acylcarnitines in serum[†]

Scheme Code: ACS

Aim: Comparison of Acylcarnitines analysis in a lab with respect to median and target values.

Status: Operating as a separate full EQA scheme since 2017; several acylcarnitines were previously included in the Special Assays in Serum scheme.

Analytes (2027):	3-OH- Butyrylcarnitine (C4-OH)	Hexanoylcarnitine (C6)
	3-OH-Isovalerylcarnitine (C5-OH)	Isovalerylcarnitine (C5)
	3-OH- Palmitoylcarnitine (C16-OH)	Malonylcarnitine (C3-DC)
	3-OH-Stearoylcarnitine (C18-OH)	Methylmalonylcarnitine (C4-DC)
	Acetylcarnitine (C2)	Octanoylcarnitine (C8)
	Butyrylcarnitine (C4)	Oleoylcarnitine (C18:1)
	Carnitine Free (C0)	Palmitoylcarnitine (C16)
	Cis-5-Tetradecenoylcarnitine (C14:1)	Propionylcarnitine (C3)
	Decanoylcarnitine (C10)	Stearoylcarnitine (C18)
	Dodecanoylcarnitine (C12)	Tiglylcarnitine (C5:1)
	Glutaryl carnitine (C5-DC)	Total Carnitine

Scientific Advisor: Dr Pedro Ruiz-Sala

Scheme Organiser: MCA[†]

Lipids in serum[†]

Scheme Code: LIS

Aim: Comparison of the outcome of assays for various lipids in serum relevant to the diagnosis of inborn errors of metabolism, in respect to median and target values.

Status: Running as a full EQA scheme for the first time in 2026 (previously ran as a pilot scheme in 2024 and 2025).

Analytes (2027):	7-dehydrocholesterol (7-DHC)	Lathosterol
	7-ketocholesterol (7-KC)	Lyso-globotriaosylceramide (Lyso-Gb3)
	C26:0-lysophosphatidylcholine (C26:0-lysoPC)	Lyso-monosialoganglioside 1 (Lyso-GM1)
	Cholestane-3 β ,5 α ,6 β -triol	Lyso-monosialoganglioside 2 (Lyso-GM2)
	Cholesterol	Lyso-sphingomyelin (Lyso-SM)
	Coenzyme Q10	N-palmitoyl-O-phosphocholineserine (PPCS)
	Desmosterol	Sitosterol
	Glucosylsphingosine	

Non-scoring analytes[‡]: Cholesterol

Scientific Advisor: Dr Susanna Goorden

Scheme Organiser: MCA[†]

[‡] Non-scoring analytes are present in the matrix so results can be recorded for comparison between labs **BUT** the concentrations do not vary. As a result, they do not contribute to performance evaluation, and are not included in the Individual Online Annual Reports or Certificates of Participation.

[†] Full details of the scheme design for each of the Quantitative schemes are given in section 2.1.1 on page 7.

Purines and Pyrimidines (urine)[†]**Scheme Code: PPU****Aim:** Comparison of Purine and Pyrimidine analysis in a lab with respect to median and target values.**Status:** Full EQA scheme since 2000.

Analytes (2027):	5-OH Methyluracil	Deoxy-adenosine	Hypoxanthine	Thymine
	3-Ureidoisobutyric acid	Deoxy-guanosine	Inosine	Uracil
	3-Ureidopropionic acid	Deoxy-inosine	Orotic acid	Uridine
	Adenine	Deoxy-uridine	Orotidine	Xanthine
	Adenosine	Dihydro-thymine	Pseudo-uridine	
	AICAr	Dihydro-uracil	Succinyladenosine	
	Cytidine	Guanosine	Thymidine	

Non-scoring analytes[‡]: Creatinine (mmol/L), Uric acid**Scientific Advisor:** Dr Jörgen Bierau**Scheme Organiser:** MCA[†]**Quantitative Amino Acids (serum)[†]****Scheme Code: QTAS****Aim:** Comparison of Amino Acid analysis in a lab with respect to median and target values.**Status:** Full EQA scheme since 1993.

Analytes (2027):	2-Aminobutyric acid	Cystine	Leucine	Sulfocysteine
	Alanine	Glutamic acid	Lysine	Taurine
	Allo-isoleucine	Glutamine	Methionine	Threonine
	Arginine	Glycine	Ornithine	Tryptophan
	Argininosuccinic acid	Histidine	Phenylalanine	Tyrosine
	Asparagine	Homocitrulline	Proline	Valine
	Aspartic acid	Hydroxyproline	Sarcosine	
	Citrulline	Isoleucine	Serine	

Scientific Advisor: Dr Rachel Carling**Scheme Organiser:** MCA[†]**Quantitative Organic Acids (urine)[†]****Scheme Code: QTOU****Aim:** Comparison of Organic Acid analysis in a lab with respect to median and target values.**Status:** Full EQA scheme since 1993.

Analytes (2027):	2-Methylcitric acid	Adipic acid	Mevalonic acid
	2-OH-Glutaric acid	Ethylmalonic acid	N-acetylaspartic acid
	3-Methylglutaconic acid	Fumaric acid	Pyroglutamic acid
	3-Methylglutaric acid	Glutaric acid	Sebacic acid
	3-OH-3-Methylglutaric acid	Hexanoylglycine	Suberic acid
	3-OH-Butyric acid	Isovalerylglycine	Suberylglycine
	3-OH-Glutaric acid	Keto-glutaric acid	Tiglylglycine
	3-OH-Isovaleric acid	Malic acid	Vanillactic acid
	3-OH-Propionic acid	Malonic acid	
	4-OH-Butyric acid	Methylmalonic acid	

Non-scoring analytes[‡]: Creatinine (mmol/L)**Scientific Advisor:** Mme Clothilde Roux**Scheme Organiser:** MCA[†]

[‡] Non-scoring analytes are present in the matrix so results can be recorded for comparison between labs BUT the concentrations do not vary. As a result, they do not contribute to performance evaluation, and are not included in the Individual Online Annual Reports or Certificates of Participation.

[†] Full details of the scheme design for each of the Quantitative schemes are given in section 2.1.1 on page 7.

Special Assays in dried blood spots[†]**Scheme Code: SADB****Aim:** To educate and assess the ability of laboratories to analyse analyte levels in dried blood spots (DBS).**Status:** Full EQA scheme since 2019.

Analytes (2027):	Alloisoleucine	Methionine	Total Homocysteine
	Carnitine Free (C0)	NTBC (nitisone)	Tyrosine
	Isoleucine	Phenylalanine	Valine
	Leucine	Succinylacetone	

Scientific Advisor: Dr Rachel Carling**Scheme Organiser:** MCA[†]**Special Assays in Serum[†]****Scheme Code: SAS****Aim:** Comparison of outcome in heterogeneous group of lab-assays, relevant to the diagnosis of inborn errors of metabolism, in respect to median and target values.**Status:** Full EQA scheme since 1993.

Analytes* (2027):	3 OH Butyric acid	Cholesterol	Methylmalonic acid
	7-Dehydrocholesterol	Creatine	Phytanic acid
	C22:0 Behenic acid	Galactose	Pipecolic acid
	C24:0 Lignoceric acid	Guanidinoacetic acid	Pristanic acid
	C26:0 Cerotic acid	Homocysteine	Pyruvic acid
	Carnitine Free	Lactic acid	Succinylacetone

Non-scoring analytes[‡]: Biotinidase, Cholesterol, FGF21, GDF15, NEFA**Scientific Advisor:** Dr Rafael Artuch**Scheme Organiser:** MCA[†]

* Note since 2026, some lipid analytes have moved from the SAS scheme to the LIS scheme, see Page 4.

Special Assays in Urine[†]**Scheme Code: SAU****Aim:** Comparison of outcome of a heterogeneous group of lab-assays, relevant to the diagnosis of inborn errors of metabolism, in respect to median and target values.**Status:** Full EQA scheme since 1993.

Analytes (2027):	4-OH-Glutamic acid	Glycolic Acid	Orotic acid
	5-Aminolevulinic acid	Guanidinoacetic acid	Oxalic acid
	5-OH-Indolacetic acid	Homocitrulline	Phosphoethanolamine
	Carnitine Free	Homogentisic acid	Pipecolic acid
	Creatine	Homovanillic acid (HVA)	Sialic acid
	Creatinine	Lactic acid	Succinylacetone
	D,L-Glyceric acid	L-Cystine	Sulfocysteine
	Galactitol	MPS (Chondroitin sulfate)	

Scientific Advisor: Dr Rafael Artuch**Scheme Organiser:** MCA[†]**Special Assays Combined****Scheme Code: SAC**

If you wish to order both the Special Assays in Serum and Special Assays in Urine scheme please select 'Special Assays Combined (serum + urine)' when submitting your order on the registration website and a discount for ordering both schemes will be applied to your order (see the EQA scheme price list on page 16).

[‡] Non-scoring analytes are present in the matrix so results can be recorded for comparison between labs BUT the concentrations do not vary. As a result, they do not contribute to performance evaluation, and are not included in the Individual Online Annual Reports or Certificates of Participation.

[†] Full details of the scheme design for each of the Quantitative schemes are given in section 2.1.1 on page 7.

2.1.1. Quantitative EQA Schemes' summary

Full detail of the analytes included in each scheme can be found on pages 4 to 6. For the provisional 2027 scheme calendar, see Section 3 on page 15.

Detailed scheme information on page:	ACS	LIS	PPU	QTAS	QTOU	SADB	SAS	SAU
	p4	p4	p5	p5	p5	p6	p6	p6
General								
Eligibility Requirements:	Participants must produce their own results and cannot send samples to a sub-contracted (or cluster) laboratory							
Use of cluster labs allowed?	No							
Educational participation allowed? *	Yes							
No. of registrations (2026):	127	69	51	265	137	119	243	193
Geographic area:	Worldwide							
Sample volume/vial	0.5ml	1ml	2.5ml	1ml	5ml	75 µl initial blood volume	5ml	5ml
Matrix of human origin, spiked with commercially available analytes	Yes							
Matrix:								
Dried blood spots	Yes							
Lyophilised plasma/serum	Yes	Yes		Yes			Yes	
Lyophilised urine			Yes		Yes			Yes
Sample treated with gentamicin	No						Yes	No
Scheme Design								
Sample design/selection:	Scientific Advisor for each scheme							
Sample manufacture subcontracted to:	MCA							
Sample aliquoting subcontracted to:	MCA							
Sample Dispatch subcontracted to:	MCA: one dispatch per year							
Country samples will be dispatched from:	Netherlands							
No of samples/year:	8							
Results Submissions								
No of submission deadlines/year:	8							
Submission of results:	online (ERNDIM-MCA website)							
Scoring of results:								
Analysis scored	Yes							
Reports:								
Interim Reports								
Published 14 days after each submission deadline	Yes							
Individual Lab Annual Reports								
Published 14 days after the last submission deadline	Yes							
Scheme Annual Reports (AR)	published in Jan-Mar of the following year							
Full anonymised scheme results included in AR	No							

* = For more information on Educational Participation see Section 5.7 of the Participants' Guide section of this catalogue on page 18;

2.2. Hybrid EQA Schemes

The main purposes of the Hybrid schemes are to evaluate the ability of the participating laboratories to: 1) quantitatively analyse the concentrations of the analytes included in each scheme; **and** 2) establish or exclude a specific diagnosis of an Inherited Metabolic Disease (IMD).

Details of the analytes included in each Hybrid scheme are below and full details of the scheme design (type and number of samples, subcontracted activities etc.) are given in section 2.2.1 on page 10.

Cluster Laboratories

Each participating laboratory must produce its own results and cannot send samples to a subcontracted or cluster laboratory. **The use of cluster laboratories is therefore not allowed in any of the Hybrid schemes.**

Cystine in White Blood Cells^{††}

Scheme Code: CWBC

Aim: Comparison of analysis of Cystine in White Blood Cells (WBC).

Status: Full EQA scheme since 2005.

No. of samples/year: 8 pairs of protein and WBC supernatants

Volume/sample: Lyophilised pellet and 250µl supernatant equivalent to extracts from 5 ml whole blood samples

Sample matrix: Lyophilised pellet from protein standard, WBC supernatants are liquid

Analytes (2027): Cystine/protein ratio (nmol 1/2 cys/mg protein)
Cystine (SNT sample) (nmol/aliquot)
Protein (PP sample) (mg /pellet)

Scientific Advisor: Mr Roger Bramley

Scheme Organiser: MCA^{††}

Lysosomal Enzymes (fibroblasts)^{††}

Scheme Code: LEFB

Aim: Testing of reproducibility and ability to detect enzyme deficiencies in lysosomal storage disorders.

Status: Full EQA scheme since 2011.

Expected Enzymes	acid sphingomyelinase	beta-glucuronidase
(2027):	alpha-galactosidase	beta-hexosaminidase A
	alpha-glucosidase	beta-hexosaminidase A+B
	alpha-N-acetyl-glucosaminidase	iduronate-sulphatase
	beta-galactosidase	lysosomal acid lipase

Scientific Advisor: Dr Ed Jacobs

Scheme Organiser: MCA^{††}

Neurotransmitters in Cerebrospinal Fluid (CSF)^{††}

Scheme Code: NCSF

Aim: To educate and assess the ability of laboratories to diagnose inborn errors of neurotransmitter metabolism.

Status: Full EQA scheme since 2016.

Analytes (2027):	3-methyl dopa (3-MD)	Biopterin
	5-OH-Indolacetic acid (5-HIAA)	Homovanillic acid (HVA)
	5-OH-Tryptophan (5-HTTP)	HVA:5-HIAA ratio
	5-methyltetrahydrofolic acid (5-MTHF)	Neopterin

Scientific Advisor: Dr Simon Pope

Scheme Organiser: MCA^{††}

^{††} Full details of the scheme design for each of the Hybrid schemes are given in section 2.2.1 on page 10.

Pterins in Urine^{††}**Scheme Code: PTU**

Aim: To educate and assess the ability of laboratories to diagnose inborn errors of tetrahydrobiopterin (BH₄) metabolism.

Status: Full EQA scheme since 2017.

Analytes (2027): Creatinine (mmol/L)

Biopterin (μmol/L & mmol/mol Creat)

Neopterin (μmol/L & mmol/mol Creat)

Primapterin (μmol/L & mmol/mol Creat)

Scientific Advisor: Dr Alessio Cremonesi

Scheme Organiser: MCA^{††}

^{††} Full details of the scheme design for each of the Hybrid schemes are given in section 2.2.1 on page 10.

2.2.1. Hybrid EQA Schemes' summary

Full detail of the analytes included in each scheme can be found on pages 8 to 9. For the provisional 2027 scheme calendar, see Section 3 on page 15.

Detailed scheme information on page:	CWBC	LEFB	NCSF	PTU
	p8	p8	p8	p9
General				
Eligibility Requirements:	Participants must produce their own results and cannot send samples to a sub-contracted (or cluster) laboratory			
Use of cluster labs allowed?	No			
Educational participation allowed? *	Yes			
No. of registrations (2026):	37	67	34	29
Geographic area:	Worldwide			
EQA Samples				
Sample volume/vial	Lyophilised protein pellet	250µl supernatant	0.5 mg lyophilised protein	1ml
Sample type				
Artificial/human matrix spiked with commercially available analytes			Yes	
Clinical samples		Yes		
Matrix of human origin, with commercially available analytes	Yes			Yes
Matrix:				
Lyophilised cerebrospinal fluid			Yes	
Lyophilised fibroblasts		Yes		
Lyophilised protein	Commercial protein standard (human origin)			
Lyophilised urine				Yes
White blood cells	Yes			
Scheme Design				
Sample design/selection:	Scientific Advisor for each scheme			
Sample manufacture subcontracted to:	MCA	CHU Lyon & MCA	MCA	University Children's Hospital, Zurich & MCA
Sample aliquoting subcontracted to:	MCA			
Sample Dispatch subcontracted to:	MCA: one dispatch per year			
Country samples will be dispatched from:	Netherlands			
No of samples/year:	8**	6	8	8
Results Submissions				
No of submission deadlines/year:	8	2	8	8
Submission of results:	online (ERNDIM-MCA website)			
Quantitative results submission is mandatory	Yes			
Interpretation results submission is mandatory	Yes			
Scoring of results:				
Analysis scored	Yes			
Diagnoses Scored	Yes			
Reports:				
Interim Reports				
Published 21 days after the last submission deadline	Yes			
Individual Lab Annual Reports				
Published after the autumn SAB meeting	Dec	-	Dec	Dec
Scheme Annual Reports (AR)	published in Jan-Mar of the following year			
Full anonymised scheme results included in AR	-	Yes	-	-

* = For more information on Educational Participation see Section 5.7 of the Participants' Guide section of this catalogue on page 18;

** = 8 pairs of protein and WBC supernatants, see CWBC scheme information on page 8.

2.3. Qualitative EQA Schemes

The main purpose of the Qualitative schemes is to evaluate the ability of the laboratory to establish or exclude a specific diagnosis of an Inherited Metabolic Disease (IMD). Participants are expected to obtain correct analytical results, to recognize the characteristic diagnostic patterns, to make a diagnostic conclusion and to suggest additional test(s) necessary to confirm the diagnosis. These schemes use clinical samples as the EQA materials.

Details of the analyte groups included in each Qualitative scheme are below and full details of the scheme design (number of samples, submission deadlines, subcontracted activities etc.) are given in section 2.3.1 on page 14.

When schemes are organised by more than one centre, participants will be assigned to a centre by the Administration Office.

Sample Donations

For some Qualitative schemes, a 20% discount on the scheme price is available to participants that donated a sample that was used as an EQA material in the previous scheme year. The Admin Office will automatically add this discount to the invoices for qualifying laboratories after the order has been submitted. For more details, please contact admin@erndim.org.

Cluster Laboratories

For DPT, the use of cluster laboratories is permitted where this reflects routine clinical practice. Responsibility for the submitted results remains with the participating laboratory, and the use of cluster laboratories must be declared when results are submitted.

For QLOU and ACDB, the use of cluster laboratories is only permitted where this reflects routine clinical practice, however, interpretation of the results must be performed by the participating laboratory, and responsibility for the submitted results remains with the participating laboratory. The use of cluster laboratories must be declared when results are submitted.

Acylcarnitines in Dried Blood Spots⁺⁺⁺

Scheme Code: ACDB

Aim: To educate and assess the ability of laboratories to detect inherited disorders resulting in recognisable whole blood acylcarnitine profiles

Status: Operated since 2003 (London only). In 2010 and 2017 additional centres in Heidelberg and Zurich, respectively were added due to increasing participant numbers. In 2018 Rome replaced Zurich as the third centre.

Eligibility Requirements: The use of cluster laboratories is only permitted where this reflects routine clinical practice. The participating laboratory must interpret the results independently and remains responsible for the submitted results.

Analytes: Dependent upon disorder

Scientific Advisors: Heidelberg: Dr Joachim Janda
London: Mrs Erin Emmett
Rome: Dr Cristiano Rizzo

Scheme Organisers: CSCQ⁺⁺⁺

Amino Acids Interpretation⁺⁺⁺

Scheme Code: AAI

Aim: To educate and assess the ability of laboratories to diagnose inherited disorders resulting in recognisable patterns of amino acids in plasma and other specimens

Status: Running as a full EQA scheme for the first time in 2023 (previously ran as a pilot scheme in 2017-2019 & 2021-2022)

Eligibility Requirements: Participating laboratories must carry out the interpretation of the EQA sample data. **The use of cluster laboratories is not allowed.**

Samples: Clinical information and quantitative values for amino acids in plasma, urine and CSF (with reference ranges) are circulated.

Note: samples are data only, no physical samples are circulated for this scheme

Analytes: Amino acids (data only)

Scientific Advisor: Dr Sabine Scholl-Bürgi

Scheme Organisers: ERNDIM

⁺⁺⁺ Full details of the scheme design for each of the Qualitative schemes are given in section 2.3.1 on page 14.

Congenital Disorders of Glycosylation (plasma/serum)⁺⁺⁺**Scheme Code: CDG**

Aim: Qualitative interpretation of sialotransferrin profiles in the screening for Congenital Disorders of Glycosylation (CDG).

Status: Full EQA scheme since 2010

Eligibility Requirements: Participating laboratories must carry out both the analysis **and** interpretation of the EQA samples. **The use of cluster laboratories is not allowed.**

Volume/sample: 25 microlitres

(If you require extra sample volume in order to carry out the analysis, a maximum of 2 extra sample sets per participant can be purchased at a discounted price (see page 16), however please note that availability is limited due to the nature of the EQA materials. Please contact admin@erndim.org if you would like further details.)

Analytes: Sialotransferrin isoforms

Scientific Advisor: Dr Dulce Quelhas

Scheme Organiser: MCA and CSCQ⁺⁺⁺

Diagnostic Proficiency Testing (urine)⁺⁺⁺**Scheme Code: DPT**

Aim: To assess test selection, analysis, interpretation and advice in the performance of tests related to the detection of inherited metabolic disorders.

Operated since 1990 (Netherlands only). In 1998 a further 3 organising centres were added (Czech

Status: Republic, France and UK) and in 2006 a fifth centre (Switzerland) was added as part of the EuroGentest project. [ERNDIM allocates labs to a centre broadly based on geographical area].

Eligibility Requirements: **Any urine sample can be sent that a laboratory operating to expected standards would be able to diagnose, but participants should be able to perform this core panel of tests:** amino acids, organic acids, oligosaccharides, mucopolysaccharides, purines & pyrimidines. If your laboratory does not offer this core panel of tests it may not be possible to obtain satisfactory performance, and we strongly recommend that you do not register for the DPT scheme. *The use of cluster labs, for instance for purines & pyrimidines, is acceptable but the participant lab is responsible for the results submitted.*

Analytes: Dependent upon disorder

Scientific Advisors: Czech Republic: Mr Petr Chrastina
France: Dr Christine Vianey-Saban
Netherlands: Dr George Ruijter
Switzerland: Dr Déborah Mathis
UK: Mrs Joanne Croft

Scheme Organiser: CSCQ⁺⁺⁺

Qualitative Organic Acids (urine)⁺⁺⁺**Scheme Code: QLOU**

Aim: To educate and assess the ability of laboratories to detect inherited disorders resulting in recognisable patterns of organic acid excretion.

Status: Operated since 1992 (Sheffield only), with additional centres in Heidelberg and Barcelona added in 2002 and 2018, respectively, due to increased participant numbers.

Eligibility Requirements: The use of cluster laboratories is only permitted where this reflects routine clinical practice. The participating laboratory must interpret the results independently and remains responsible for the submitted results.

Analytes: Dependent upon disorder

Scientific Advisors: Barcelona: Dr Judit Garcia-Villoria
Heidelberg: Dr Joachim Janda
Sheffield: Mrs Camilla Scott

Scheme Organiser: CSCQ⁺⁺⁺

⁺⁺⁺ Full details of the scheme design for each of the Qualitative schemes are given in section 2.3.1 on page 14.

Urine Mucopolysaccharides^{†††}**Scheme Code: UMPS**

Aim: To educate and assess the ability of laboratories to detect mucopolysaccharidoses.

Status: Full EQA scheme since 2012.

Eligibility Requirements: Participating laboratories must carry out both the analysis **and** interpretation of the EQA samples. **The use of cluster laboratories is not allowed.**

Analytes: Quantitative (related to creatinine) and qualitative analysis of mucopolysaccharides with interpretation of results obtained

Scientific Advisor: Dr Berthil Prinsen

Scheme Organiser: MCA and CSCQ^{†††}

^{†††} Full details of the scheme design for each of the Qualitative schemes are given in section 2.3.1 on page 14.

2.3.1. Qualitative EQA Schemes' Design summary

Full details of the analyte groups included in each scheme can be found on pages 11 to 13. For the provisional 2027 scheme calendar, see Section 3 on page 15.

Detailed scheme information on page:	DPT	ACDB	QLOU	AAI	CDG	UMPS
	p12	p11	p12	p11	p12	p13
General						
Method Orientated scheme?	No	Yes				
Eligibility Requirements:	See DPT information on p12	See ACDB information on p11	See QLOU information on p12	Participants must produce their own results and cannot send samples/cases to a sub-contracted (or cluster) laboratory		
Use of cluster labs allowed?	Yes	Yes ¹	Yes ¹	No		
Educational participation allowed? ²	No	Yes	Yes	No	Yes	
No of organising centres:	5	3	3	1	1	1
No. of registrations (2026):	96 (16-21 per centre)	140 (46-47 per centre)	230 (76-77 per centre)	148	52	86
Geographic area:	Worldwide					
EQA Samples						
Sample volume/vial:	5-10ml	30-50µl	2-3 ml/vial	n/a	25 µl ³	5ml
Sample type	Clinical samples			Data from clinical samples	Clinical samples	
Matrix:						
Data from plasma, urine & CSF samples				Yes		
Dried Blood Spots on S&S903 filter paper		Yes				
Heat treated urine	Yes		Yes			
Lyophilised plasma/serum					Yes	
Lyophilised urine						Yes
Scheme Design						
Sample design/selection	Scientific Advisors (SA) for each scheme					
Sample aliquoting subcontracted to:	CSCQ	SA	CSCQ	n/a	MCA	MCA
Sample Dispatch subcontracted to: (one dispatch per year)	CSCQ	CSCQ	CSCQ	n/a	MCA	MCA
Country samples will be dispatched from:	Switzerland ⁴	Switzerland ⁴	Switzerland ⁴	n/a	Netherlands	Netherlands
No of samples/year	6					
Results Submissions						
No of submission deadlines/year	2					
Submission of results	Online (ERNDIM-CSCQ website)			Online (ERNDIM form)	Online (ERNDIM-CSCQ website)	
Scoring of results:						
Analysis of physical samples	Yes			No	Yes	
Analysis of data samples only	No			Yes	No	
Interpretation, including diagnoses	Yes					
Reports:						
Interim Reports						
Published 8-10 weeks after the submission deadline	Yes					
Diagnoses circulated by email 2-3 weeks after submission deadline	Yes					
Individual Lab Annual Reports						
Published following moderation of scoring at the Autumn Scientific Advisory Board meeting	Yes					
Scheme Annual Reports (AR)	Published in Jan-Mar of the following year					
Full anonymised scheme results included in AR	Yes					

¹ = The use of cluster labs is permitted under specific circumstances. Please refer to the eligibility requirements in Section 2.3

² = For more information on Educational Participation see Section 5.7 of the Participants' Guide section of this catalogue on page 18;

³ = see CDG scheme information on page 12.

⁴ = For Italy and Spain, the sample parcel will be dispatched from the Netherlands

3. 2027 Calendar (provisional)

Please note the schedules in this calendar are provisional only. Please check the EQA calendar on the EQA tab of the ERNDIM website (www.erndim.org), which, from the end of January 2027, will be updated with confirmed dates as they become available.

Year	Month	Quantitative Schemes								Hybrid Schemes				Qualitative Schemes							
		ACS	LIS	PPU	QTAS	QTOU	SADB	SAS	SAU	CWBC	LEFB	NCSF	PTU	ACDB	AAI	CDG	DPT	QLOU	UMPS		
-1	Sep	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R		
	Oct	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R		
	Nov																				
	Dec																				
	Jan																				
Scheme Year	Feb	D	D	D	D	D	D	D	D	D	D	D	D	D		D	D	D	D		
	Mar	S	S	S	S	S	S	S	S	S		S	S								
	Apr	S	S	S	S	S	S	S	S	S		S	S	S			S				
	May	S	S	S	S	S	S	S	S	S	S	S	S		D	S		S	S		
	Jun	S	S	S	S	S	S	S	S	S		S	S	S	S		S				
	Jul	S	S	S	S	S	S	S	S	S		S	S								
	Aug	S	S	S	S	S	S	S	S	S	S	S	S		D						
	Sep	S	S	S	S	S	S	S	S	S		S	S		S	S		S	S		
	Oct	S	S	S	S	S	S	S	S	S		S	S								
	Nov																				
	Dec																				
+1	Jan	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL	PSL		
	Feb	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A		
	Mar	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR		
		C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C		

R = Registration open

D = Sample Dispatch

S = Submission Deadline

PSL = Performance Support Letters sent

A = Appeals open

AR = EQA scheme Annual Reports published

C = Certificates of Participation published

4. 2027 Price List



EQA Schemes	Scheme Code	2027 Prices		
		Euro	GB Pounds	US\$
1. Quantitative Schemes				
Acylcarnitines in Serum	ACS	460	415	542
Lipids in Serum	LIS	266	240	313
Purines and Pyrimidines (urine)	PPU	510	461	602
Quantitative Amino Acids (serum)	QTAS	422	381	498
Quantitative Organic Acids (urine)	QTOU	484	437	571
Special Assays in Dried Blood Spots	SADB	349	315	412
Special Assays (serum)	SAS	274	248	324
Special Assays (urine)	SAU	260	234	306
Special Assays Combined (serum & urine)	SAC	478	431	563
2. Hybrid Schemes				
Cystine in White Blood Cells	CWBC	523	472	617
Lysosomal Enzymes (fibroblasts)	LEFB	901	814	1063
Neurotransmitters (CSF)	NCSF	526	475	620
Pterins in Urine	PTU	510	460	601
3. Qualitative Schemes				
Acylcarnitines (dried blood spots) *	ACDB	478	431	563
Amino Acids Interpretation	AAI	184	156	188
Congenital Disorders of Glycosylation (serum) *	CDG	488	441	576
First set charged at full price; extra sets charged at**	CDG	283	256	334
Diagnostic Proficiency Testing (urine) *	DPT	681	614	803
Qualitative Organic Acids (urine) *	QLOU	513	463	605
Urine Mucopolysaccharides *	UMPS	457	413	539
Mailing fee per scheme for all laboratories:		46	40	54

Please note:

- VAT at 20% will be added to invoices for all UK laboratories.
- The mailing fee per scheme will be added to the invoices for ALL laboratories unless the laboratory provides their own courier account number to be used for sample dispatch.
- *** For these schemes a 20% discount on the scheme price is available to participants that donated a sample that was used as an EQA material in the previous scheme year.** The Admin Office will automatically add this discount to the invoices for qualifying laboratories after the order has been submitted. For more details, please contact admin@erndim.org.
- **** Orders for CDG are limited to 3 per laboratory.** If you wish to order more than 3 sample sets please let us know and we will contact you after the registration period has closed.

5. Participation Guide

5.1. Registering for EQA Schemes

Registration for the next year's EQA schemes opens in the September of the previous year and is only available for a defined period. For the 2027 EQA schemes, registration will be open from **mid-September to late-October 2026** (see www.erndim.org for the exact dates).



In some circumstances late registration may be possible but will be dependent upon sample availability and the agreement of the relevant Scientific Advisor.

Details of how to access the ERNDIM Registration Website (www.eqa.erndim.org) are sent to all existing EQA participants in September of each year and are available from the ERNDIM Administration office upon request.

All EQA scheme orders **must** be submitted using the ERNDIM Registration Website.

On rare occasions, if an EQA scheme is oversubscribed, orders placed within the registration period, and the participation of clinical diagnostic laboratories will be prioritised over laboratories that do not offer a clinical service.

If your laboratory already participates in an ERNDIM EQA scheme the Registration Website will show all the contact and address information which is held by ERNDIM for your laboratory.

It is the responsibility of the person listed as the primary laboratory contact to provide the ERNDIM Administration office with valid, up to date contact and address details:

1. The primary laboratory contact should check that all the information is correct and update it where necessary. The information should include:

- Email addresses for primary and secondary contact persons*.
- Email address for named Head of Laboratory or Quality Manager*. *If a laboratory does not supply the contact details for the Head of laboratory or Quality Manager, ERNDIM reserves the right to withhold the laboratory's Certificate of Participation until such time as the contact details are supplied (see section 5.14.).*

* These contact details must be for 3 different people.

- A postal address for the participating laboratory.
- A delivery address for EQA materials.
- An invoice address and named invoice contact with email address.

2. Select the EQA schemes that you wish to participate in during the next year.

3. Add a purchase order number to the registration form, if your hospital or laboratory procedures require it to be on the invoice, and then,

4. Submit your order.

Any subsequent change in contact persons or address details **must** be sent to the ERNDIM Administration office (admin@erndim.org) as soon as possible.

New participants should email the ERNDIM Administration Office to request access to the ERNDIM Registration Website.

If you have any problems with registering for the EQA schemes, please contact admin@erndim.org.

5.2. Terms & Conditions of EQA scheme registration

All participant laboratories must accept the terms and conditions on the ERNDIM Registration Website before an EQA scheme order can be submitted. The terms and conditions are on page 23 of this catalogue and can also be viewed on the ERNDIM Registration Website.

5.3. Confidentiality

Laboratory information is confidential and is only shared with the ERNDIM Administration Office, the Scientific Advisors and the scheme organisers. All participating laboratories are given a unique ERNDIM reference number which should be used in all correspondence with ERNDIM.

The fact that your laboratory participates in ERNDIM schemes is not confidential, however, the raw data and performance scores are confidential and will only be shared within ERNDIM for the purpose of evaluating your laboratory's performance (which may include sharing information between the ERNDIM schemes that you subscribe to), unless ERNDIM is required to disclose performance data by a relevant government agency.



Please see the terms and conditions on page 23 for details of our confidentiality policy for laboratory information; and the [ERNDIM Privacy Policy](http://www.erndim.org) on www.erndim.org, for details of the personal information we collect and store, and your rights regarding that data.

5.4. Use of ERNDIM EQA data in publications

Data derived from the use or analysis of ERNDIM EQA materials **must not** be used in written publications or oral presentations unless the explicit prior consent of ERNDIM has been granted.

If you wish to use data derived from ERNDIM EQA materials, you **must** contact the Administration Office to obtain permission **before** publication.

For EQA materials based on real clinical samples, permission to use the data will be dependent on the appropriate consent being in place.

If permission to use the data is granted, ERNDIM must be acknowledged in the publication or presentation using a standard acknowledgement sentence which will be provided by the ERNDIM Administration Office, and a copy of the publication, with full reference/citation information, should be sent to the ERNDIM Administration Office.

5.4.1. Use of ERNDIM data to train AI

In all cases, the use of any ERNDIM related data for training artificial intelligence systems is strictly prohibited. ERNDIM data includes, but is not limited to, data derived from the use or analysis of ERNDIM EQA materials, or present in any ERNDIM scheme or other reports.

5.5. EQA participation fees

The price list for the 2027 EQA schemes can be found on page 16 of this catalogue.

A mailing charge per scheme will be added to the EQA order unless the details of a courier account to be used for sample dispatch are provided by the participant.

VAT at 20% will be added to invoices for all UK laboratories.

5.6. Laboratory Support Grants

A limited number of Laboratory Support Grants are available to provide financial support for laboratories which due to financial restrictions find it difficult to fund participation in one or more of the ERNDIM EQA schemes.

Laboratory Support Grants are awarded annually by the ERNDIM Board on a competitive basis with the aim of allowing laboratories to extend their repertoire of EQA scheme participation.



If you would like to apply for a Laboratory Support Grant please complete and return the application form, which can be found on the ERNDIM website under [EQA Schemes/Laboratory Support Grants](#).

Applications for support during the 2027 scheme year must be received by the Administration Office during the registration period.

5.7. Educational Participation

Educational Participation is open to laboratories that are participating in an EQA scheme to help with setting up a new test but are not yet offering a clinical service.

Participants that select Educational Participation when registering for an EQA scheme **MUST** send a completed and signed Educational Declaration form to the ERNDIM Administration office.

Educational Participation in a scheme is not confirmed until the Administration Office confirms that your application has been accepted.

Please note the number of Educational Participants per scheme is limited and Educational Participation is not available for the AAI or DPT schemes.

The Educational Participation Declaration forms can be found on the ERNDIM Registration website (www.eqa.erndim.org) under Participant Information. There is one form for the qualitative schemes and separate forms for each of the quantitative and hybrid schemes.



For each EQA scheme in which you wish to be an Educational Participant, a separate Declaration form needs to be completed, and sent to admin@erndim.org.

5.8. Sample Donation

Several of the ERNDIM EQA schemes use real clinical samples as the EQA materials however, it is becoming increasingly difficult to source suitable clinical samples. Details of the types of samples that would be useful to ERNDIM can be found on the [EQA schemes tab of the ERNDIM website](#). If you think you would be able to donate a clinical sample (with the appropriate patient consent) to ERNDIM please contact admin@erndim.org.

5.8.1. Scheme Discounts

If a sample donated by your laboratory is used as an EQA material in one of the Qualitative EQA schemes, you will qualify for a 20% discount on the cost of that specific scheme when you register for the following scheme year. The Administration Office automatically applies this discount to orders from qualifying laboratories once the order has been submitted.

The maximum discount that can usually be applied is 20% per laboratory per scheme regardless of how many donated samples are used in a scheme year.

5.9. EQA scheme timetables

A provisional EQA calendar is on page 15. From the end of January in each year, the EQA calendar will also be available to download on the [ERNDiM website under EQA schemes](#). Information is added to the calendar as it becomes available.

5.10. Sample Dispatches

Sample dispatch dates will be given on the ERNDiM website by the end of January but are usually in early February. Additionally, all participants will be sent emails with dispatch information 1-2 weeks before sample dispatch.

5.10.1. Replacement Samples

If you do not receive the EQA sample parcel within the time specified in the sample dispatch alert email please contact the ERNDiM Administration Office (admin@erndim.org).



5.11. Analysis and Reporting

You will receive instructions on sample testing and reporting processes with the sample shipments. Scheme instructions will also be available to download from the ERNDiM Registration website (www.ega.erndim.org) under Participant Information, or by contacting admin@erndim.org. EQA samples must be analysed in the normal way your laboratory would treat routinely tested patient samples including the use of routine measurement or test methods.

Details of the submission deadlines for each scheme are given in the scheme instructions you will receive with the sample parcel and in the EQA calendar on the EQA schemes tab of the ERNDiM website (www.erndim.org). EQA scheme instructions can also be downloaded from the Registration Website (www.ega.erndim.org) under Participant Information.

Reports and results will be released according to individual scheme timetables. **Please note: Data derived from any EQA reports should not be used in any written publications or oral presentations unless the explicit prior consent of ERNDiM has been granted. In addition, the use of this data for training artificial intelligence systems is strictly prohibited. See item 5.4 for details.**

If a laboratory does not submit results, or submits insufficient results for performance to be assessed this will be shown on the Certificate of Participation. If this occurs in multiple years, ERNDiM also reserves the right to restrict the laboratory's participation in the EQA scheme(s) in future years.

5.11.1. Late results submission or amending submitted results

We strongly recommend that all submitted results are printed and checked before the relevant deadline. If you do miss a submission deadline or realise after the deadline that you need to amend an already submitted result, please contact admin@erndim.org as soon as possible.

However, please note that result submission extensions will only be granted under exceptional circumstances and no late/amended results can be accepted if the relevant consensus results or diagnoses have already been published.

5.12. Final Scheme Annual reports

For each EQA scheme an Annual report is published after the end of the scheme year. All the available EQA scheme Annual reports can be downloaded from the ERNDiM website under [Meeting and Reports](#).

Please note: Data derived from EQA scheme annual reports should not be used in any written publications or oral presentations unless the explicit prior consent of ERNDiM has been granted. In addition, the use of this data for training artificial intelligence systems is strictly prohibited. See item 5.4 for details.

5.13. Performance Assessment

Submitted results are evaluated according to ERNDiM policies and procedures. The frameworks for assessment for each scheme type can be found on the Participant Information tab of the Registration Website (www.ega.erndim.org) under Assessment and Education.

The number of points required for satisfactory performance in each EQA scheme is defined by the Scientific Advisor, ratified by the Scientific Advisory Board (SAB) and is reviewed annually.

Satisfactory performance in an EQA scheme is based solely on the laboratory's performance in that scheme year and does not guarantee future performance.

ERNDiM is not responsible for the performance of participating laboratories.



5.13.1. Critical Errors

For the Qualitative and Hybrid EQA schemes any errors which would be unacceptable to the majority of laboratories will be separately assessed as Critical Errors.

An absence of Critical Errors is required for satisfactory performance. Any laboratory that makes

a Critical Error will be classed as a poor performer regardless of their overall score in the EQA scheme.

The critical errors for each scheme year will be proposed by the Scientific Advisors for the individual EQA schemes and will be ratified at the SAB Meeting held after the completion of the EQA scheme year.

Lists of the Critical Errors agreed for previous scheme years can be found on the ERNDIM website under [Meetings & Reports/Other Reports](#).

5.13.2. Performance Support Letters

Laboratories that have unsatisfactory performance or fail to return sufficient results will be sent a Performance Support Letter by ERNDIM.

The aim of the performance support letter is to begin a dialogue between the Scientific Advisor and the participating laboratory in order to solve any particular analytical problems and to help the laboratory improve performance.

If a laboratory does not respond to the Performance Support Letter, ERNDIM reserves the right to contact the Laboratory Head or Quality Manager.

Performance Support Letters will also be sent to the Laboratory Head or Quality Manager for cases of Global Poor Performance (poor performance in more than one EQA scheme in one year) and Persistent Poor Performance (poor performance in an EQA scheme for at least 2 out of 3 years during which the participant has submitted results).

In the rare instances that a lab is a Persistent Global Poor Performer (poor performance in more than one EQA scheme in at least 2 out of 3 participating years) ERNDIM reserves the right to contact the administration of the relevant institution.

5.14. Certificates of Participation

A certificate showing which EQA schemes you have registered for, participated in and your laboratory's performance in those schemes is issued after the end of the scheme year when all scheme results have been finalised.

ERNDIM reserves the right to withhold the certificate of participation in cases where:

- The relevant ERNDIM invoice has not been paid.
- The Head of Laboratory or Quality Manager contact has not been provided.
- A laboratory has been found to be colluding, or is strongly suspected of colluding, with another laboratory (see section 5.15).



5.15. Collusion

Participants found to be colluding, or which are strongly suspected of colluding, with another laboratory in their scheme returns may have their certificates of participation withheld and be excluded from participation in future schemes.

5.16. Appeals, Complaints & Feedback

Problems relating to EQA Schemes, including appeals and complaints from participating laboratories, should be referred directly to the ERNDIM Administration Office (admin@erndim.org).

5.16.1. Appeals

If you wish to appeal against the evaluation of your laboratory's performance in an EQA scheme a formal appeal must be submitted using the online appeals form (link included in the performance support letter), within 4 weeks of the date of the performance support letter.

Appeals against classification as a poor performer due to score are initially considered by the EQA scheme Scientific Advisor with any further appeals being considered by the ERNDIM Executive Committee.

Appeals against classification as a poor performer due to a critical error will be considered by the Executive Committee.



5.16.2. Complaints

If a complaint is received it will be logged along with the action taken. The office staff will attempt to address the complaint as soon as possible. If the participant is not satisfied with the response then the matter will be brought to the Executive Committee at their next meeting and a response made in light of their advice.

5.16.3. Feedback to ERNDIM

Confidential communications about a scheme can be made to the Administration Office.

A participant survey is also conducted annually. The results of this survey are shared with the ERNDIM Management Committees and a survey report is uploaded to the ERNDIM website under [Meetings and Reports](#).

5.17. Subcontracted Activities

Some activities such as the manufacture of materials, dispatch of samples and hosting and maintenance of websites are subcontracted but ERNDIM remains responsible for the oversight of subcontracted activities.

Details of the sub-contracted activities for each scheme are included in the scheme information in section 2 of this catalogue and are also available on the EQA schemes tab of the ERNDIM website (www.eqa.erndim.org).

5.18. Training Support Grants

As part of our aim to help improve standards in biochemical genetic testing, ERNDIM offers a small number of Training Support Grants each year.

This grant is designed for trainees, in a permanent laboratory position, to gain experience and knowledge in a European ERNDIM approved laboratory in order to develop or introduce new methods to their own laboratory.

Funds can be applied for to cover the travel and accommodation costs incurred by such visits and a maximum of 6 grants will be awarded each year, subject to the approval of the ERNDIM Executive Committee. Full application criteria are given in the application form which can be found on the ERNDIM website under [Training/Training Support Grants](#).



5.19. Invoicing & Payment Information

5.19.1. Invoices

For participants that submit an EQA scheme order by the Registration deadline, invoices will be sent out in December and will be dated 1st January of the following year, as requested by a number of laboratories.

If your hospital or laboratory procedures require a purchase order number be included on the invoice, this should be added to your order on the ERNDIM Registration Website.

If you receive a purchase order number from your finance department after the Registration period has closed, please send it to the Administration Office as soon as possible so it can be added to your invoice.

The invoice payment date will be stated on the invoice but for orders submitted within the Registration period, **invoice payments must be received by ERNDIM by 1st April in the scheme year**, unless an earlier date due to late payment of a previous invoice is specified.

The invoice of participants that submit a late registration request will be dated with the issued date and the payment date will be 1st April or 8 weeks from the issued date; whichever is later.

Invoices show:

- The EQA schemes chosen.
- The subscription fees for those schemes and associated mailing charges.
- Any discounts applied due to sample donation or awarded grants.

Invoices will be sent by email only to the primary, secondary and invoice contacts for each laboratory. It is the responsibility of the primary laboratory contact to ensure they provide a valid invoice address, invoice contact name and invoice email address.

The participant **must** check the information in the invoice. If all details are correct the invoice should be passed for payment to the appropriate finance department.

If any details on the invoice are not correct the ERNDIM Administration office (admin@erndim.org) should be notified by the end of December and a revised invoice will be issued.

It is the responsibility of the participant laboratory to ensure that the ERNDIM invoice is paid.

Late payment will incur penalties as specified below:

- Interest charges of 1.3% per month may be applied to outstanding balances after the invoice payment date. When interest is added to the outstanding balance an updated invoice with a new version number will be sent to the participant.
- If there is still an outstanding invoice balance after the 1st July, in the next year the invoice payment date will be 31st January and the dispatch of samples to the laboratory in that year will be delayed until ALL outstanding invoices have been paid.
- If there is still an outstanding invoice balance after the 1st August, access to the EQA scheme results will be restricted until the invoice has been paid.
- If there is still an outstanding invoice balance after the 1st September, in the same year as the scheme participation, the laboratory will not be eligible to register for any ERNDIM EQA schemes until all outstanding invoices have been paid and a Certificate of Participation for the current year will not be issued.



5.19.2. Payment Information

ERNDIM accepts payments in Euro, GB pounds or US dollars and it is important that the correct bank account is used for payments in each currency.

Payments which are made into the wrong bank

account (for example a payment in Euros paid into the GB pounds account) can result in losses due to the bank exchange rate. **Any losses which are a result of a participant making a payment into the wrong ERNDIM bank account, will be borne by the participant.**

ERNDIM is responsible solely for paying its own bank charges. Any other charges related to invoice payments must be paid by the participant.

All correspondence and invoice payments MUST contain your laboratory's ERNDIM reference number (ERNxxxx) otherwise it may not be possible to match the payment to the correct account.

Unfortunately payments by cheque cannot be accepted.

ERNDIM bank accounts.

- For payments in **Euros** please use:

STICHING ERNDIM QAP

Barclays Bank PLC, SHEFFIELD CITY,
Leicester, LE87 2BB, UK

Account Number: 65615322

Sort Code: 20-76-89

SWIFT Address: BUKBGB22

IBAN: GB76 BUKB20768965615322

- For payments in **GB Pounds** please use:

STICHING ERNDIM QAP

Barclays Bank PLC, SHEFFIELD CITY,
Leicester, LE87 2BB, UK

Account Number: 70540900

Sort Code: 20-76-89

SWIFT Address: BUKBGB22

IBAN: GB59 BUKB20768970540900

- For payments in **US Dollars** please use:

STICHING ERNDIM QAP

Barclays Bank PLC, SHEFFIELD CITY,
Leicester, LE87 2BB, UK

Account Number: 44300511

Sort Code: 20-76-89

SWIFT Address: BUKBGB22

IBAN: GB40 BUKB20768944300511

6. Terms and Conditions of EQA Scheme Participation for Participating Centres

Use of data derived from ERNDIM EQA Materials

1. Data derived from the use or analysis of ERNDIM EQA materials **must not be** used in written publications or oral presentations unless the explicit prior consent of ERNDIM has been granted.

1. If a participating laboratory wishes to use such data in a publication or presentation, they **must** contact the ERNDIM Administration Office before submitting any documents for publication.
2. For EQA materials based on real clinical samples, permission to use the data will be dependent on the appropriate consent being in place.
3. If permission to use the data is granted: a) ERNDIM must be acknowledged in the publication or presentation using a standard acknowledgement sentence which will be provided by the ERNDIM Administration Office, and b) after the data has been published a copy of the publication, with full reference/citation information, should be sent to the ERNDIM Administration Office.

2. Use of ERNDIM data to train artificial (AI) intelligence systems

1. The use of any ERNDIM related data for training AI systems is strictly prohibited. ERNDIM data includes, but is not limited to, data derived from the use or analysis of ERNDIM EQA materials, or present in any ERNDIM scheme or other reports.

3. Use of ERNDIM Logo and Website Materials

1. Participants may use the ERNDIM Participant Logo only to indicate their participation in ERNDIM EQA schemes and must comply with ERNDIM's Logo and Website Materials Policy (which can be found on www.erndim.org); use of the ERNDIM name, main logo, or website materials for any other purpose requires prior written permission from ERNDIM.

Registering for EQA Schemes

4. When registering for ERNDIM EQA schemes it is the responsibility of the person listed as the laboratory primary contact to provide the ERNDIM Administration office with valid, up to date contact and address details, which should include:

1. Email and postal addresses for primary and secondary contact persons* (these contacts will be used for all routine ERNDIM correspondence)
2. Email address for named Head of Laboratory or Quality Manager* (this contact will only be used in certain cases of poor performance or if the primary and secondary contacts persistently do not respond to ERNDIM correspondence)
3. A postal address for the registering Laboratory
4. A delivery address for EQA materials
5. An invoice address and named invoice contact with email address

** these contact details must be for 3 different people*

Any subsequent change in contact persons or address details **must** be sent to the ERNDIM Administration Office as soon as possible.

5. Participants are responsible for ensuring that they have obtained any import or other permits required for delivery of the EQA materials and for sending these to the ERNDIM Administration office during the Registration period.

6. Mailing charges (per scheme) will be added to the EQA order unless the participant provides the details of a courier account to be used for the sample dispatch. Any additional customs charges will be paid by the participant.

7. For participants that submit an EQA scheme order by the Registration deadline, invoices will be sent out in December and will be dated 1st January of the following year, as requested by a number of laboratories.

Invoices and Payments

8. If your hospital or laboratory procedures require a Purchase Order number on the invoice, this should be added to the registration form.

9. **Invoices will be sent by email only to the primary, secondary and invoice contacts for each laboratory.** It is the responsibility of the primary laboratory contact to provide a valid invoice address, invoice contact name and invoice email address.

10. The participant **must** check the information in the invoice. If all details are correct the invoice should be passed for payment to the appropriate finance department. If any details on the invoice are not correct the ERNDIM Administration office (admin@erndim.org) should be notified by the end of December and a revised invoice will be issued.

11. The invoice payment date will be stated on the invoice but for orders submitted within the registration period, **invoice payments must be received by ERNDIM by 1st April in the scheme year**, unless an earlier date due to late payment of a previous invoice is specified

12. For participants that submit a late registration request any invoices will be dated with the issued date and the payment date will be 1st April or 8 weeks from the issued date, whichever is later.

13. **It is the responsibility of the participant laboratory to ensure that the ERNDIM invoice is paid.**

14. ERNDIM accepts payments in Euro, GB pounds or US dollars and it is important that the correct bank account is used for payments in each currency. Payments which are made into the wrong bank account (for example a payment in Euros paid into the GB pounds account) can result in losses due to the bank exchange rate. Any losses which are a result of a participant making a payment into the wrong ERNDIM bank account will be borne by the participant.

15. ERNDIM is responsible solely for paying its own bank charges. Any other charges related to invoice payments must be paid by the participant.

16. Penalties for late payment of invoices are:

1. Interest charges of 1.3% per month may be applied to outstanding balances after the invoice payment date. When interest is added to the outstanding balance an updated invoice will be generated;
2. If there is still an outstanding invoice balance after the 1st July, in the following year the invoice payment date of any invoices will be 31st January and the dispatch of samples to the laboratory in the that year will be delayed until ALL outstanding invoices have been paid;
3. If there is still an outstanding invoice balance after the 1st August, access to the EQA scheme results will be restricted until the invoice has been paid;
4. If there is still an outstanding invoice balance after the 1st September, in the same year as the scheme

participation, the laboratory will not be eligible to register for any ERNDIM EQA schemes until all outstanding invoices have been paid and a Certificate of Participation for the current scheme year will not be issued.

EQA Scheme Participation

17. EQA samples must be treated in the same way as routinely tested clinical samples, including the use of routine measurements or test methods.

18. Compliance with the EQA submission deadlines is a requirement of satisfactory participation in the EQA schemes.

1. Requests for late submissions will only be allowed under **exceptional** circumstances and as such requests for late submission on more than one occasion will not routinely be accepted.
2. No late/amended results can be accepted if the relevant consensus results or diagnoses have already been published.

19. Participants must not collude with other laboratories on the results of their EQA scheme participation. This includes the use of cluster labs unless these are specifically allowed in the individual EQA scheme.

1. Laboratories which have been found to have colluded and/or falsified results will be excluded from participating in future EQA schemes and where necessary, the relevant competent authority will be notified.
2. In cases where collusion is strongly suspected, ERNDIM reserves the right to withhold the certificate of participation for the specified scheme year from the relevant laboratories and may also exclude the laboratories from participating in future EQA schemes.

20. All participating laboratories are given a unique ERNDIM reference number which should be used on all invoice payments and in all correspondence with ERNDIM.

21. The fact that your laboratory participates in ERNDIM schemes is not confidential, however, the raw data and performance scores are confidential and will only be shared within ERNDIM for the purpose of evaluating your laboratory's performance, (which may include sharing information between the ERNDIM schemes that you subscribe to) except in these circumstances:

1. Performance information of United Kingdom laboratories may be shared with NQAAP, for French laboratories performance information may be shared with ANSM.
2. If ERNDIM is approached by other equivalent national bodies, ERNDIM may share performance information with those bodies, but in that case the labs concerned would be informed in advance. For countries with fewer than 5 participating laboratories, to preserve anonymity, only regional data will be shared.

Performance Evaluation

22. Satisfactory performance in an EQA scheme is based solely on the laboratory's performance when analysing the EQA samples supplied in that scheme year. By participating in ERNDIM schemes participants agree to these terms and conditions. The frameworks for assessment for each scheme type can be found on the Participant Information tab of the Registration Website (www.eqa.erndim.org).

23. ERNDIM is not responsible for the performance of participating laboratories when offering a clinical diagnostics service.

24. Laboratories that have unsatisfactory performance will be sent a Performance Support Letter by ERNDIM. If a laboratory does not respond to the Performance Support Letter, or has persistent unsatisfactory performance, ERNDIM reserves the right to contact the Laboratory Head or Quality Manager.

25. For laboratories that have unsatisfactory performance in more than one EQA scheme during one scheme year (i.e. Global Poor Performance) ERNDIM reserves the right to contact the Laboratory Head or Quality Manager. For laboratories that have persistent Global Poor Performance ERNDIM reserves the right to contact the CEO or equivalent of the relevant institution.

26. Laboratories that do not submit any results, or do not submit sufficient results for their performance to be evaluated, will be sent a Non-submission letter. If a laboratory does not respond to the Non-submission Letter, or persistently does not submit sufficient results for their performance to be evaluated ERNDIM reserves the right to contact the Laboratory Head or Quality Manager and may restrict eligibility for future scheme years.

27. If a laboratory does not supply the contact details for the Laboratory Head or Quality Manager, ERNDIM reserves the right to withhold the laboratory's Certificate of Participation until such time as the contact details are supplied.

Data Protection & Privacy

28. Any personal information you supply to ERNDIM via this website will be treated in accordance with the [ERNDIM Privacy Policy](http://www.erndim.org) (which can be found on www.erndim.org) and the UK's Data Protection Act 2018, which is the UK's implementation of the EU General Data Protection Regulation (GDPR) 2016.

29. By using this website, you consent to ERNDIM processing any data you provide in line with the [ERNDIM Privacy Policy](http://www.erndim.org) and confirm that all data provided by you is accurate. If there are any changes to the data you have provided, it is your responsibility to update such data.

Problems & Complaints

30. Problems relating to EQA Schemes, including complaints from participating laboratories should be referred directly to the ERNDIM Administration Office (admin@erndim.org).

Copyright

31. All documents, and the data they contain, issued by ERNDIM are copyright and must **not** be published in any form without the permission of the ERNDIM Executive Committee.